CN111372944A - 新型γδT细胞受体和其配体 - Google Patents

新型γδT细胞受体和其配体 Download PDF

Info

Publication number
CN111372944A
CN111372944A CN201880074771.1A CN201880074771A CN111372944A CN 111372944 A CN111372944 A CN 111372944A CN 201880074771 A CN201880074771 A CN 201880074771A CN 111372944 A CN111372944 A CN 111372944A
Authority
CN
China
Prior art keywords
tcr
cell
clone
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880074771.1A
Other languages
English (en)
Chinese (zh)
Inventor
A·苏厄尔
G·多尔顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Original Assignee
University College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd filed Critical University College Cardiff Consultants Ltd
Publication of CN111372944A publication Critical patent/CN111372944A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
CN201880074771.1A 2017-11-20 2018-11-16 新型γδT细胞受体和其配体 Pending CN111372944A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1719169.3 2017-11-20
GBGB1719169.3A GB201719169D0 (en) 2017-11-20 2017-11-20 Novel T-cell receptor and ligand
PCT/GB2018/053321 WO2019097244A1 (en) 2017-11-20 2018-11-16 Novel gamma delta t-cell receptor and its ligand

Publications (1)

Publication Number Publication Date
CN111372944A true CN111372944A (zh) 2020-07-03

Family

ID=60805814

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880074771.1A Pending CN111372944A (zh) 2017-11-20 2018-11-16 新型γδT细胞受体和其配体

Country Status (15)

Country Link
US (1) US11850264B2 (https=)
EP (1) EP3713954A1 (https=)
JP (1) JP2021505190A (https=)
KR (1) KR20200085776A (https=)
CN (1) CN111372944A (https=)
AU (1) AU2018369698A1 (https=)
BR (1) BR112020007469A2 (https=)
CA (1) CA3079156A1 (https=)
EA (1) EA202091276A1 (https=)
GB (1) GB201719169D0 (https=)
IL (1) IL274482A (https=)
MX (1) MX2020005200A (https=)
SG (1) SG11202002993UA (https=)
WO (1) WO2019097244A1 (https=)
ZA (1) ZA202002417B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230226183A1 (en) * 2020-01-15 2023-07-20 The Regents Of The University Of California Compositions and methods for altering gamma delta t cell activity
EP4059955A1 (en) 2021-03-19 2022-09-21 Medizinische Hochschule Hannover Hla-dr-specific gamma delta tcr constructs and use thereof
EP4472742A1 (en) 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
US20240043496A1 (en) * 2022-07-26 2024-02-08 Gadeta B.V. Delta t-cell or gamma receptor chains or parts thereof for treating ovarian cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013593A2 (en) * 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO2016146618A1 (en) * 2015-03-16 2016-09-22 Max-Delbrück-Centrum für Molekulare Medizin Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library
CN106103490A (zh) * 2014-03-19 2016-11-09 塞勒克提斯公司 用于癌症免疫疗法的cd123特异性嵌合抗原受体
CN106922148A (zh) * 2014-07-29 2017-07-04 瑟勒提斯公司 用于癌症免疫疗法的ror1(ntrkr1)特异性的嵌合抗原受体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260223A (en) * 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
AU2002308481A1 (en) * 2001-05-01 2002-11-11 Senomyx, Inc. High throughput cell-based assay for monitoring sodium channel activity and discovery of salty taste modulating compounds
AU2002359666A1 (en) * 2001-12-10 2003-06-23 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
CN1842709A (zh) * 2003-07-10 2006-10-04 塞诺米克斯公司 使用表达人的ENaC的卵母细胞的改进的电生理测定法和用于在使用膜电位报告染料的测定中提高ENaC增强子功效的PHENAMIL的用途
WO2013155406A1 (en) * 2012-04-12 2013-10-17 The Chinese University Of Hong Kong Contragestion and treating inflammation by modulating sodium channel activity in the epithelium
WO2015121454A1 (en) * 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
MX2016014434A (es) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013593A2 (en) * 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
CN106103490A (zh) * 2014-03-19 2016-11-09 塞勒克提斯公司 用于癌症免疫疗法的cd123特异性嵌合抗原受体
CN106922148A (zh) * 2014-07-29 2017-07-04 瑟勒提斯公司 用于癌症免疫疗法的ror1(ntrkr1)特异性的嵌合抗原受体
WO2016146618A1 (en) * 2015-03-16 2016-09-22 Max-Delbrück-Centrum für Molekulare Medizin Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MATEUSZ LEGUT ET AL: "\"The promise of [gamma][delta] T cells and the [gamma][delta] T cell receptor for cancer immunotherapy", CELLULAR & MOLECULAR IMMUNOLOGY, vol. 12, no. 6, pages 656 - 668 *
MOUNIA S. BRAZA ET AL: "Anti-tumour immunotherapy with V[gamma]9V[delta]2 T lymphocytes: from the bench to the bedside\"", BRITISH JOURNAL OF HAEMATOLOGY, vol. 160, no. 2, pages 123 - 132 *

Also Published As

Publication number Publication date
ZA202002417B (en) 2021-07-28
US11850264B2 (en) 2023-12-26
US20200316124A1 (en) 2020-10-08
CA3079156A1 (en) 2019-05-23
AU2018369698A1 (en) 2020-04-30
MX2020005200A (es) 2020-08-20
JP2021505190A (ja) 2021-02-18
SG11202002993UA (en) 2020-06-29
BR112020007469A2 (pt) 2020-11-03
EA202091276A1 (ru) 2020-09-04
WO2019097244A1 (en) 2019-05-23
IL274482A (en) 2020-06-30
EP3713954A1 (en) 2020-09-30
KR20200085776A (ko) 2020-07-15
GB201719169D0 (en) 2018-01-03

Similar Documents

Publication Publication Date Title
US11078252B2 (en) T-cell receptor
KR102609624B1 (ko) 방법
EP3664820B1 (en) Methods for producing genetically engineered cell compositions and related compositions
EP3775229A1 (en) Modified immune cells having enhanced function and methods for screening for same
KR20200108278A (ko) 조작된 ｔ 세포의 조성물을 제조하는 방법
CA3085606A1 (en) Enhanced chimeric antigen receptors and uses thereof
CA3045338A1 (en) Production of engineered cells for adoptive cell therapy
WO2017044661A1 (en) Ny-eso-1 specific tcrs and methods of use thereof
US11850264B2 (en) Gamma delta T-cell receptor and its ligand
JP2022527813A (ja) Ｍａｇｅａ１特異的ｔ細胞受容体およびその使用
US12479903B2 (en) CD5 specific T cell receptor cell or gene therapy
US20210403528A1 (en) Novel T-Cell Receptor and Ligand
EA045252B1 (ru) Новый т-клеточный рецептор
HK40034405B (en) Novel t-cell receptor
HK40034405A (en) Novel t-cell receptor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200703